scholarly journals Retinoic Acid Inhibits CD25+Dendritic Cell Expansion and γδ T-Cell Activation in Experimental Autoimmune Uveitis

2013 ◽  
Vol 54 (5) ◽  
pp. 3493 ◽  
Author(s):  
Dongchun Liang ◽  
Aijun Zuo ◽  
Hui Shao ◽  
Willi K. Born ◽  
Rebecca L. O'Brien ◽  
...  
2018 ◽  
Vol 62 (3) ◽  
pp. 398-406 ◽  
Author(s):  
Atsunobu Takeda ◽  
Hisakata Yamada ◽  
Eiichi Hasegawa ◽  
Mitsuru Arima ◽  
Shoji Notomi ◽  
...  

2017 ◽  
Vol 10 (02) ◽  
pp. 1650042 ◽  
Author(s):  
Beibei Wang ◽  
Wei Lin ◽  
Jike Song ◽  
Xiaofeng Xie ◽  
Hongsheng Bi

Uveitis is a severe inflammatory disease that can cause visual impairment. Recently, activated [Formula: see text] T cells were proved to play a central role in the development of experimental autoimmune uveitis (EAU). However, the mechanism underlying [Formula: see text] T-cell activation in EAU is incompletely known. In this study, we determined the percentage changes in and the phenotypes of [Formula: see text] T cells and dendritic cells (DCs) obtained from the spleens of immunized C57BL/6 (B6) mice, an animal model of EAU. We found that the number of [Formula: see text] T cells and DCs obviously increased during the inflammation phase of EAU (days 16–20 of our experiment), and that during this time, [Formula: see text] T cells expressed high levels of CD69 and the integrin lymphocyte function–associated antigen-1 (LFA-1) and secreted high levels of interleukin (IL)-17A. Moreover, DCs obtained during this phase expressed high levels of CD80, CD83, CD86, and intracellular cell adhesion molecule-1 (ICAM-1). Furthermore, we studied the interaction between DCs and [Formula: see text] T cells by using flow cytometry and confocal microscopy in order to determine whether DCs affected [Formula: see text] T-cell activation in vitro. Co-cultures of the two types of cells showed that DCs induced high levels of CD69, LFA-1, and IL-17A in [Formula: see text] T cells. Imaging studies revealed contact between the DCs and [Formula: see text] T cells. This interaction was mediated by the accumulation of ICAM-1 and LFA-1 at the interface of DCs-[Formula: see text] T cells. Thus, the activation of [Formula: see text] T cells in EAU was promoted by DCs interacting with [Formula: see text] T cells.


2018 ◽  
Vol 38 (3) ◽  
pp. 233-243 ◽  
Author(s):  
Dongchun Liang ◽  
Hui Shao ◽  
Willi K. Born ◽  
Rebecca L. O'Brien ◽  
Henry J. Kaplan ◽  
...  

Author(s):  
Margarete D. Johnson ◽  
Michel F. Otuki ◽  
Daniela A. Cabrini ◽  
Ross Rudolph ◽  
Deborah A. Witherden ◽  
...  

Oncogene ◽  
2021 ◽  
Author(s):  
Francesca Alfei ◽  
Ping-Chih Ho ◽  
Wan-Lin Lo

AbstractThe exploitation of T cell-based immunotherapies and immune checkpoint blockade for cancer treatment has dramatically shifted oncological treatment paradigms and broadened the horizons of cancer immunology. Dendritic cells have emerged as the critical tailors of T cell immune responses, which initiate and coordinate anti-tumor immunity. Importantly, genetic alterations in cancer cells, cytokines and chemokines produced by cancer and stromal cells, and the process of tumor microenvironmental regulation can compromise dendritic cell–T cell cross-talk, thereby disrupting anti-tumor T cell responses. This review summarizes how T cell activation is controlled by dendritic cells and how the tumor microenvironment alters dendritic cell properties in the context of the anti-tumor immune cycle. Furthermore, we will highlight therapeutic options for tailoring dendritic cell-mediated decision-making in T cells for cancer treatment.


Sign in / Sign up

Export Citation Format

Share Document